GlassScriptPhysician profile
Inna Shmerlin
NPI 1689696569
$58,760.94
in general payments reported to CMS, 2019-2025
62 companies · $6,086 in 2025
The $6,086 reported for 2025 was more than what 76% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $8,046 · 2021: $1,529 · 2022: $6,467 · 2023: $8,790 · 2024: $14K · 2025: $6,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $3,993 · Food and Beverage: $3,890 · Honoraria: $1,800 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,404.00 |
| Travel and Lodging | $3,993.14 |
| Food and Beverage | $3,890.08 |
| Honoraria | $1,800.00 |
| Education | $199.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,855.27 | 2020-2025 | Imfinzi, Lynparza, Calquence |
| Exelixis INC. | $5,921.88 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $4,568.41 | 2023-2025 | Brukinsa |
| Seagen INC. | $4,522.98 | 2019-2025 | |
| Cti Biopharma Corp. | $4,500.00 | 2022 | |
| Genzyme Corporation | $3,546.13 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $3,006.44 | 2023 | Monoferric |
| Johnson & Johnson Health Care Systems INC. | $2,940.00 | 2023 | Darzalex |
| Celgene Corporation | $2,513.06 | 2019-2025 | Reblozyl |
| Janssen Biotech, INC. | $2,032.49 | 2019-2025 | Akeega, Erleada, Carvykti |
| G1 Therapeutics, INC. | $1,500.00 | 2021 | |
| Taiho Oncology, INC. | $1,130.00 | 2024 | |
| Daiichi Sankyo INC. | $682.01 | 2022-2025 | Enhertu |
| Beigene, LTD. | $450.00 | 2020 | |
| Novocure Gmbh | $400.00 | 2022 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Chiesi USA, INC. | $300.00 | 2025 | Ferriprox |
| E.R. Squibb & Sons, L.L.C. | $285.60 | 2024-2025 | Opdivo, Eliquis |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $248.32 | 2021-2025 | |
| Tempus Ai, INC | $241.81 | 2025 | Xt Cdx |
| Alexion Pharmaceuticals, INC. | $240.62 | 2022-2025 | Ultomiris |
| Sirtex Medical INC | $182.69 | 2019-2025 | Sir-Spheres Microspheres |
| Incyte Corporation | $158.23 | 2022-2024 | Jakafi |
| Pfizer INC. | $154.37 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.37 | 2019-2025 | Fruzaqla, Advate, Ninlaro |
| Array Biopharma INC | $132.89 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Abbvie INC. | $131.00 | 2024-2025 | |
| Integra Lifesciences Corporation | $110.99 | 2023 | Duraseal Exact Spinal Sealant System, Codman Certas, Codman Hakim |
| Comsort, INC | $100.00 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $99.00 | 2020 | |
| Servier Pharmaceuticals LLC | $71.89 | 2024-2025 | |
| Kite Pharma, INC. | $65.24 | 2025 | Yescarta |
| Merck Sharp & Dohme LLC | $61.96 | 2024-2025 | Keytruda, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $61.32 | 2023-2025 | Libtayo, Lynozyfic |
| Secura Bio, INC. | $60.37 | 2024 | Copiktra |
| Siemens Medical Solutions USA, INC. | $60.10 | 2019 | |
| Legend Biotech USA INC. | $56.01 | 2025 | Carvykti |
| Glaxosmithkline, LLC. | $55.24 | 2023-2024 | Zejula, Jemperli, Ojjaara |
| Eisai INC. | $52.63 | 2023-2025 | |
| Gilead Sciences, INC. | $50.39 | 2021-2025 | Trodelvy |
| Blueprint Medicines Corporation | $44.16 | 2022-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.15 | 2024-2025 | Gilotrif |
| Lilly USA, LLC | $38.78 | 2024 | Verzenio, Retevmo, Jaypirca |
| Bayer Healthcare Pharmaceuticals INC. | $38.32 | 2019 | |
| Puma Biotechnology, INC. | $34.60 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $24.53 | 2024 | Empaveli |
| Shield Therapeutics INC | $23.07 | 2025 | |
| Jazz Pharmaceuticals INC. | $22.88 | 2025 | |
| Dendreon Pharmaceuticals LLC | $22.29 | 2024 | Provenge |
| Adc Therapeutics America, INC. | $20.05 | 2025 | |
| Stemline Therapeutics INC. | $19.61 | 2024 | Orserdu |
| Genentech USA, INC. | $19.15 | 2024 | Itovebi, Phesgo |
| Caris Mpi, INC. | $17.07 | 2025 | Mi Cancer Seek |
| Foundation Medicine, INC. | $16.21 | 2023 | |
| Tersera Therapeutics LLC | $16.13 | 2025 | Zoladex |
| Acrotech Biopharma INC. | $15.38 | 2024 | Beleodaq |
| Novo Nordisk INC | $13.95 | 2024 | Esperoct |
| Astellas Pharma US INC | $12.90 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Shmerlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.